Stock jumped 31% on announcement of strategic partnership with Eli Lilly. The deal provides revenue opportunities, access to advanced AI research tools, and positions the company as a key participant in a major pharmaceutical innovation initiative.
Articles that tag TWST but are mainly about other companies.
Despite Ark's selling activity, the article emphasizes Ark's substantial remaining holdings ($332M+), strong revenue growth (13 consecutive quarters), and 190% year-to-date gains. The selling is characterized as profit-taking rather than a loss of confidence. However, the article notes the company still reports net losses and carries high risk.
13 consecutive quarters of revenue growth (19% increase in latest quarter). Stock up 136% in past year. Strategic partnership with Amazon Bio Discovery positions company as key supplier for AI-driven drug development pipeline. Higher-risk profile but significant upside potential.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
